
    
      The study is a multi-target gene-modified immunotherapy. CAR-T/TCR-T cells include four
      different tumor-specific antibody.They are as following:anti-NY-ESO-1 antibody foresophagus
      cancer;anti-DR5 antibody for hepatoma;;anti-EGFR vIII antibody for hepatoma and
      glioma;anti-Mesothelin antibody for gastric cancer.
    
  